AstraZeneca (LON:AZN) Given Buy Rating at Shore Capital

Share on StockTwits

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by equities researchers at Shore Capital in a report issued on Wednesday, ThisIsMoney.Co.Uk reports.

Several other research analysts also recently weighed in on AZN. Citigroup reaffirmed a “buy” rating and set a £100 ($130.67) target price (up from GBX 7,000 ($91.47)) on shares of AstraZeneca in a research note on Wednesday, September 11th. Jefferies Financial Group increased their price objective on AstraZeneca from GBX 6,550 ($85.59) to GBX 6,700 ($87.55) and gave the company a “hold” rating in a research note on Tuesday, October 15th. UBS Group reissued a “sell” rating on shares of AstraZeneca in a research note on Monday, September 30th. Bank of America reissued a “buy” rating and issued a GBX 8,500 ($111.07) price objective on shares of AstraZeneca in a research note on Tuesday, October 8th. Finally, Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a research note on Friday, September 20th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and a consensus price target of GBX 7,137.81 ($93.27).

Shares of AZN stock opened at GBX 6,803 ($88.89) on Wednesday. The company has a debt-to-equity ratio of 144.48, a current ratio of 0.95 and a quick ratio of 0.74. The company has a market cap of $89.23 billion and a price-to-earnings ratio of 39.74. The stock has a 50 day simple moving average of GBX 7,066.01 and a 200-day simple moving average of GBX 6,532.84. AstraZeneca has a 1-year low of GBX 5,312 ($69.41) and a 1-year high of GBX 8,227.88 ($107.51).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: What are the Different Types of Leveraged Buyouts?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.